SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001564590-17-007133
Filing Date
2017-04-25
Accepted
2017-04-25 16:25:32
Documents
5
Effectiveness Date
2017-04-25

Document Format Files

Seq Description Document Type Size
1 DEFA14A sgmo-defa14a_20170425.htm DEFA14A 43511
2 GRAPHIC g20170424215405354441.jpg GRAPHIC 94317
3 GRAPHIC g20170424215405379442.jpg GRAPHIC 44492
4 GRAPHIC g20170424215405331440.jpg GRAPHIC 79127
5 GRAPHIC g20170424215405397443.jpg GRAPHIC 51431
  Complete submission text file 0001564590-17-007133.txt   416180
Mailing Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804
Business Address 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND CA 94804 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

IRS No.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-30171 | Film No.: 17781367
SIC: 2836 Biological Products, (No Diagnostic Substances)